

Professor Xiaoliang Wang, Vice president of Chinese Pharmaceutical Association; vice dean of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College.

He received the master degree of pharmacology from the Peking Union Medical College, Beijing in 1982 and the Medical Doctor degree from the Essen University, Germany in 1987. He became a full Professor of pharmacology at the Institute of Materia Medica, Chinese Academy of Medical Sciences in 1993. He worked as director of the Institute of Materia Medica from 1997 to 2010.

His research interests include: fundamental pharmacology and drug development, especially the drugs for cardiovascular and neurodegenerative diseases, such as stroke, Alzheimer's disease and Parkinson Disease and so on. He has been studied the mechanisms and biomarkers of the drugs for stroke and dementia by using molecular biological, proteomics and pharmacological methods. Meanwhile, he studied and developed new anti-stroke drugs and anti-Alzheimer's disease drugs from Chinese Medicine and synthesized compounds. He has published 200 papers and filed 20 patents in China and world-wide. Since 2000 he has been the Chief-Editor of *Acta Pharmaceutica Sinica*, 2007 the Vice president of Chinese Pharmaceutical Association and Vice president of Asian Federation of Pharmaceutical Sciences, 2014 the BPS member of FIP.